Establishment Labs Holdings Inc. (ESTA) — SEC Filings
Establishment Labs Holdings Inc. (ESTA) — 40 SEC filings. Latest: 8-K (May 6, 2026). Includes 23 8-K, 5 10-Q, 3 SC 13G.
View Establishment Labs Holdings Inc. on SEC EDGAR
Overview
Establishment Labs Holdings Inc. (ESTA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Establishment Labs Holdings Inc. reported a net loss of $11.146 million for the three months ended September 30, 2025, an improvement from a net loss of $16.682 million in the same period of 2024. Revenue significantly increased to $53.782 million for the quarter, up from $40.227 million in Q3 2024,
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 1 bearish, 37 neutral, 2 mixed. The dominant filing sentiment for Establishment Labs Holdings Inc. is neutral.
Filing Type Overview
Establishment Labs Holdings Inc. (ESTA) has filed 23 8-K, 5 10-Q, 2 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G, 3 SC 13G/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of ESTA's 31 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $53.782M |
| Net Income | $(11.146)M |
| EPS | $(0.38) |
| Debt-to-Equity | 19.71 |
| Cash Position | $70.624M |
| Operating Margin | -7.5% |
| Total Assets | $338.895M |
| Total Debt | $249.44M |
Key Executives
- Dr. Karen L. Smith
- Mr. David L. Johnson
- Mr. Juan Carlos Bonilla
- Juan Jose Chacon Quiros
Industry Context
Establishment Labs operates in the highly regulated medical device sector, specifically focusing on the breast aesthetics and reconstruction market. This industry is characterized by significant R&D investment, long product development cycles, and intense competition from both established global players and emerging companies. Key trends include demand for innovative and safer implant technologies, as well as evolving aesthetic preferences and reconstructive needs.
Top Tags
financial-reporting (5) · sec-filing (5) · 8-K (5) · financial-condition (5) · operations (4) · financials (4) · Medical Devices (3) · material-agreement (3) · 8-k (3) · disclosure (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $53.782M | Increased 33.7% from $40.227M in Q3 2024 |
| Net Loss | $(11.146)M | Improved from $(16.682)M in Q3 2024 |
| Cash and Cash Equivalents | $70.624M | Decreased from $90.347M at Dec 31, 2024 |
| Note Payable | $246.458M | Increased from $219.577M at Dec 31, 2024 |
| Net Cash Used in Operating Activities | $50.728M | For the nine months ended September 30, 2025 |
| Gross Margin | 70.1% | For the three months ended September 30, 2025 |
| Sales, General and Administrative Expenses | $37.166M | For the three months ended September 30, 2025, up from $34.055M in Q3 2024 |
| Basic and Diluted Net Loss Per Share | $(0.38) | For the three months ended September 30, 2025, improved from $(0.59) in Q3 2024 |
| Year-to-Date Net Loss | $35.1M | Widened from $29.8M in the prior year, showing sustained losses. |
| Accumulated Deficit | $350.2M | Grew from $315.1M, reflecting continued operational losses over time. |
| Total Liabilities | $105.3M | Increased from $98.7M, suggesting growing financial obligations. |
| Total Assets | $450.5M | Slightly decreased from $455.2M, indicating a minor contraction in the asset base. |
| SEC File Number | 001-38593 | Identifies the company's filing history with the SEC. |
| EIN | 98-1436377 | Employer Identification Number for tax purposes. |
| Period End Date | 2025-03-31 | The end of the reporting period for this 10-Q filing. |
Forward-Looking Statements
- {"claim":"Juan Jose Chacon Quiros will maintain a significant ownership stake in Establishment Labs Holdings Inc.","entity":"Juan Jose Chacon Quiros","targetDate":"Next 12-24 months","confidence":"high"}
- {"claim":"The high insider ownership will continue to align management's interests with long-term shareholder value.","entity":"Establishment Labs Holdings Inc.","targetDate":"Ongoing","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Establishment Labs Holdings Inc. (ESTA)?
Establishment Labs Holdings Inc. has 40 recent SEC filings from Jan 2024 to May 2026, including 23 8-K, 5 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ESTA filings?
Across 40 filings, the sentiment breakdown is: 1 bearish, 37 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Establishment Labs Holdings Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Establishment Labs Holdings Inc. (ESTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Establishment Labs Holdings Inc.?
Key financial highlights from Establishment Labs Holdings Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ESTA?
The investment thesis for ESTA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Establishment Labs Holdings Inc.?
Key executives identified across Establishment Labs Holdings Inc.'s filings include Dr. Karen L. Smith, Mr. David L. Johnson, Mr. Juan Carlos Bonilla, Juan Jose Chacon Quiros.
What are the main risk factors for Establishment Labs Holdings Inc. stock?
Of ESTA's 31 assessed filings, 1 were flagged high-risk, 11 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Establishment Labs Holdings Inc.?
Recent forward-looking statements from Establishment Labs Holdings Inc. include guidance on {"claim":"Juan Jose Chacon Quiros will maintain a significant ownership stake in Establishment Labs Holdings Inc.","enti and 1 other predictions.